- Cancer-specific mortality was found to be moderately reduced in patients with gastro-oesophageal cancer using angiotensin receptor blockers (ARBs).
- In England, ARBs are recommended as a first-line pharmacological treatment for hypertension patients aged under 55 y or with comorbid diabetes.
- In-vitro models at various cancer sites have shown that ARBs reduce tumour growth, stimulate cell apoptosis, reduce metastasis, and inhibit angiogenesis.
- This cohort study evaluated 5124 patients (ARB users, n=360; non-users, n=4764) with gastro-oesophageal cancer between 1998 and 2012.
- Association between post-diagnosis ARB use and gastro-oesophageal cancer mortality was evaluated.
- Funding: Clinical Research Bursary for AS from Cancer Research-UK.
- Median follow-up duration was 1.4 y.
- 3345 patients died during the follow-up period because of gastro-oesophageal cancer.
- ARB users showed moderately reduced risk for gastro-oesophageal cancer mortality after adjustment (HR, 0.83) vs non-users.
- Mortality rate was found to be significantly lower among patients receiving ARBs for at least 2 y (HR, 0.42; P-value for trend=.003).
- Dose-response relationship showed slightly stronger association among patients with gastric cancer (aHR, 0.79) vs oesophageal cancer (aHR, 0.89).
- Cancer-specific deaths were not identifiable.